Abstract

Over the past five years, the Chinese pharmaceutical industry has experienced new opportunities and challenges with the implementation of a new round of medical reforms nationwide. Since the outbreak of the COVID-19 pandemic in 2019, the increasing awareness of health and the continuous demand for medical services have led to a sustained growth in demand for traditional Chinese medicine products and services in China. This study takes a comprehensive fundamental analysis approach, incorporating relevant knowledge from finance, to examine the financial indicators and development of Yiling Pharmaceutical Co., Ltd., a typical company in the pharmaceutical industry. Through financial statement analysis, the profitability of Yunnan Baiyao is assessed, along with the prediction of debt-paying ability during the evaluation process. Lastly, a fundamental analysis is conducted to summarize the strengths and weaknesses of Yiling Pharmaceutical Co., resulting in the conclusion of its investment value.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call